Better Prices Buoy Immucor
Immucor
(BLUD)
said price increases helped fourth-quarter revenue rise nearly 40% from a year ago, and the company provided a forecast for the upcoming fiscal year that falls in the range of Wall Street's estimates.
Revenue for the fiscal fourth quarter was $42.1 million, up 39.2% from $30.2 million in the same period last year. Of the total increase, about $9.8 million came from higher prices.
TheStreet Recommends
Net income for the quarter totaled $9.2 million, or 19 cents a share, vs. a profit of $3.4 million, or 7 cents a share, last year.
Immucor, which sells reagents and systems used to identify the properties of blood prior to a transfusion, said it expects revenue for the fiscal year ending May 31, 2006, of $190 million to $204 million, with earnings of 95 cents to $1.05.
Shares of Immucor, of Norcross, Ga., were up 7% to $29.20.
Analysts surveyed by Thomson First Call expected a profit of 20 cents a share with revenue of $43.4 million in the quarter. The consensus estimates for the 2006 fiscal year are earnings of $1.01 and revenue of $195.5 million.
